Showing 1081-1090 of 1781 results for "".
- Aflibercept 8 mg Sustains 96-Week Outcomes in PULSAR nAMD Trialhttps://reachmd.com/news/aflibercept-8-mg-sustains-96-week-outcomes-in-pulsar-namd-trial/2487292/Key Takeaways Week 96 visual and anatomic outcomes were maintained, and BCVA differences versus 2q8 met the noninferiority criteria specified for the primary end point at week 48. Extended intervals were common with aflibercept 8 mg among patients comp
- Left Atrial Appendage Closure vs Medical Therapy in Atrial Fibrillationhttps://reachmd.com/news/left-atrial-appendage-closure-vs-medical-therapy-in-atrial-fibrillation/2487197/Key Takeaways Left atrial appendage closure was not noninferior to physician-directed best medical care for the composite end point. A total of 912 adults with atrial fibrillation at high risk for stroke and bleeding were randomized to device therapy o
- Phase 2 Readouts: Lunsekimig Met Endpoints in Asthma and CRSwNPhttps://reachmd.com/news/phase-2-readouts-lunsekimig-met-endpoints-in-asthma-and-crswnp/2486541/Key points: Lunsekimig met primary and key secondary endpoints in Phase 2 studies in asthma and CRSwNP The therapy targets both TSLP and IL-13 via a bispecific Nanobody® design An exploratory Phase 2 study in atopic dermatitis did not meet its
- CLL Associated With Increased Skin Cancer Risk and Worse Outcomeshttps://reachmd.com/news/cll-associated-with-increased-skin-cancer-risk-and-worse-outcomes/2486544/Key points: Cohort study of more than 13,000 patients with psoriasis evaluated paradoxical eczema risk during biologic therapy Overall incidence was low (~1%), but varied by drug class IL-23 inhibitors were associated with the lowest risk comp
- First Patient Dosed in OYE Therapeutics IV Caffeine 505(b)(2) Bridging Studyhttps://reachmd.com/news/first-patient-dosed-in-oye-therapeutics-iv-caffeine-505b2-bridging-study/2486542/Key points: First patient dosed in a 505(b)(2) bridging study of OYE-101 OYE-101 is an intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation Study will generate human data to support a future 505(b)
- New AAFPRS Data Reveals Trends Defining Facial Plastic Surgeryhttps://reachmd.com/news/new-aafprs-data-reveals-trends-defining-facial-plastic-surgery/2485807/The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) is reporting a notable shift in the aesthetic landscape, with its 2025 Annual Survey pointing to rising procedural volume alongside evolving patient priorities. According to newly released data, facial plastic surgeons nat
- Systematic Review Supports Efficacy of Targeted HA Chin Injection Strategyhttps://reachmd.com/news/systematic-review-supports-efficacy-of-targeted-ha-chin-injection-strategy/2485670/Chin augmentation with hyaluronic acid (HA) fillers has become a cornerstone of lower facial contouring. In a systematic review and meta-analysis published online in Aesthetic Plastic Surgery, the authors evaluated the safety and efficacy of a two-three-point injection technique for chin
- Artemisia Extracts vs H1N1: Preclinical Mechanisms and Translational Next Stepshttps://reachmd.com/news/artemisia-extracts-vs-h1n1-preclinical-mechanisms-and-translational-next-steps/2485607/Three Artemisia plant extracts were tested against influenza A/H1N1 in a cell-based preclinical system, pointing to a potentially multi-modal development path that pairs virus-directed interference at entry and egress (hemagglutinin-mediated attachment and neuraminidase activity) wi
- Advancements in Predicting Postoperative Reintubation Riskhttps://reachmd.com/news/advancements-in-predicting-postoperative-reintubation-risk/2484639/A new point-based risk score identifies patients at elevated risk of reintubation within 24 hours and reduces unrecognized events—its discrimination (AUROC 0.831) supports targeted postoperative and ED surveillance. Age <1 or >65 years, ASA classification ≥III,
- FDA Clears AVAVA Device for Wrinkle Treatment Across All Skin Typeshttps://reachmd.com/news/fda-clears-avava-device-for-wrinkle-treatment-across-all-skin-types/2484238/AVAVA® has received US Food and Drug Administration (FDA) clearance for the treatment of fine lines and wrinkles across Fitzpatrick skin types I-VI, marking its second clearance in recent months following its prior approval for acne scars. The nonablative platform, powered by Focal Point T